Literature DB >> 34229619

Cost effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome: the ACTIB randomised trial.

Paul McCrone1,2, Hazel Everitt3, Sabine Landau4, Paul Little3, Felicity L Bishop5, Gilly O'Reilly3, Alice Sibelli6, Rachel Holland4, Stephanie Hughes3, Sula Windgassen6, Kim Goldsmith4, Nicholas Coleman7, Robert Logan8, Trudie Chalder9, Rona Moss-Morris6.   

Abstract

BACKGROUND: Telephone therapist delivered CBT (TCBT) and web-based CBT (WCBT) have been shown to be significantly more clinically effective than treatment as usual (TAU) at reducing IBS symptom severity and impact at 12 months in adults with refractory IBS. In this paper we assess the cost-effectiveness of the interventions.
METHODS: Participants were recruited from 74 general practices and three gastroenterology centres in England. Interventions costs were calculated, and other service use and lost employment measured and costed for one-year post randomisation. Quality-adjusted life years (QALYs) were combined with costs to determine cost-effectiveness of TCBT and WCBT compared to TAU.
RESULTS: TCBT cost £956 more than TAU (95% CI, £601-£1435) and generated 0.0429 more QALYs. WCBT cost £224 more than TAU (95% CI, - £11 to £448) and produced 0.029 more QALYs. Compared to TAU, TCBT had an incremental cost per QALY of £22,284 while the figure for WCBT was £7724. After multiple imputation these ratios increased to £27,436 and £17,388 respectively. Including lost employment and informal care, TCBT had costs that were on average £866 lower than TAU (95% CI, - £1133 to £2957), and WCBT had costs that were £1028 lower than TAU (95% CI, - £448 to £2580).
CONCLUSIONS: TCBT and WCBT resulted in more QALYs and higher costs than TAU. Complete case analysis suggests both therapies are cost-effective from a healthcare perspective. Imputation for missing data reduces cost-effectiveness but WCTB remained cost-effective. If the reduced societal costs are included both interventions are likely to be more cost-effective. Trial registration ISRCTN44427879 (registered 18.11.13).

Entities:  

Keywords:  Cognitive behavioural therapy; Cost-effectiveness; Economic evaluation; Irritable bowel syndrome

Year:  2021        PMID: 34229619     DOI: 10.1186/s12876-021-01848-9

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  3 in total

1.  A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care.

Authors:  R Moss-Morris; L McAlpine; L P Didsbury; M J Spence
Journal:  Psychol Med       Date:  2009-06-17       Impact factor: 7.723

2.  Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults.

Authors:  Hazel Everitt; Sabine Landau; Paul Little; Felicity L Bishop; Paul McCrone; Gilly O'Reilly; Nicholas Coleman; Robert Logan; Trudie Chalder; Rona Moss-Morris
Journal:  BMJ Open       Date:  2015-07-15       Impact factor: 2.692

3.  Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial.

Authors:  Trudie Chalder; Rona Moss-Morris; Hazel Anne Everitt; Sabine Landau; Gilly O'Reilly; Alice Sibelli; Stephanie Hughes; Sula Windgassen; Rachel Holland; Paul Little; Paul McCrone; Felicity Bishop; Kimberley Goldsmith; Nicholas Coleman; Robert Logan
Journal:  Gut       Date:  2019-04-10       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.